An opportunity for healthcare IT
Precision oncology — a diverse set of strategies in cancer care personalized for the biology of an individual patient’s disease — is emerging, with application in 70% of US and European oncology practices.1
However, with only 14% of oncologists routinely participating in molecular tumor boards, 18% regularly using clinical decision support (CDS) tools and 41% frequently deploying targeted therapies according to a patient’s genomic alteration,1 the growth of precision oncology depends on the development of innovative IT.
An open platform to the future
NAVIFY® Decision Support portfolio operates from an open platform for software developed by Roche, partners and third parties to maximize functionality and actionable, data-driven insights.
Through NAVIFY portfolio and the ever-expanding NAVIFY Clinical Decision Support apps ecosystem, institutions may subscribe to the workflows and integrated apps that drive the efficiency, accuracy and clinician satisfaction achievements at the core of their missions.
The benefits offered by an integration and implementation of NAVIFY Tumor Board to provide all available patient data extend beyond multidisciplinary team collaboration and diagnostics processing. NAVIFY workflows enhanced by CDS apps are ready to support insights from clinical trials, scientific exploration and medical advances.